Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of, Medicine, 88 Jiefang Road, Hangzhou, 310009, China.
Department of Gastroenterology, The Third Xiangya Hospital, Central South University, 138 Tongzibo Road, Changsha, China.
Food Funct. 2024 Jun 17;15(12):6553-6564. doi: 10.1039/d3fo05391a.
Previous preclinical evidence indicates a protective role of quercetin against inflammatory bowel disease (IBD). However, there is no evidence from human populations, resulting in knowledge gaps regarding the role of quercetin in the IBD development. We aimed to prospectively evaluate the associations between dietary quercetin intake and IBD in humans and animal models. We included 187 709 IBD-free participants from the UK Biobank. Dietary information was collected using validated 24-hour dietary recalls and the quercetin intake was estimated based on national nutrient databases. Incident IBD was ascertained inpatient and primary care data. Cox proportional hazard models were used to estimate the multi-variable adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). Experiments were conducted in two chemical-induced (dextran sulfate sodium salt and trinitro-benzene-sulfonic acid) mouse models orally pretreated with quercetin (CAS number: 117-39-5) solution to evaluate the effects of quercetin at physiological levels. After a mean follow-up of 9.7 years, we documented 863 incident IBD. Compared to participants with the lowest quintile intake of quercetin, those in the highest quintiles were associated with a lower risk of IBD (aHR 0.76, 95% CI 0.60-0.95; -trend = 0.004) and ulcerative colitis (aHR 0.69, 95% CI 0.53-0.91; -trend = 0.001), but not Crohn's disease (aHR 0.95, 95% CI 0.62-1.45; -trend = 0.765). Mouse models showed that pretreatment with quercetin could attenuate the chemically induced colitis. Higher quercetin intake was associated with a lower risk of IBD, especially UC. The protective role of quercetin is promising in humans and warrants further investigation into downstream mechanisms.
先前的临床前证据表明槲皮素对炎症性肠病（IBD）具有保护作用。然而，人类群体没有这方面的证据，导致人们对槲皮素在 IBD 发展中的作用知之甚少。我们旨在前瞻性评估人类和动物模型中膳食槲皮素摄入与 IBD 之间的关联。我们纳入了来自英国生物库的 187709 名无 IBD 参与者。膳食信息通过经过验证的 24 小时膳食回忆收集，槲皮素摄入量基于国家营养数据库进行估算。IBD 的发病情况通过住院和初级保健数据确定。使用多变量调整后的风险比（aHR）和 95%置信区间（CI）来估计 Cox 比例风险模型。在两种化学诱导（葡聚糖硫酸钠盐和三硝基苯磺酸）的小鼠模型中进行了实验，这些模型通过口服预先用槲皮素（CAS 号：117-39-5）溶液预处理，以评估槲皮素在生理水平下的作用。经过平均 9.7 年的随访，我们记录了 863 例 IBD 发病。与槲皮素最低五分位数摄入的参与者相比，槲皮素最高五分位数摄入的参与者患 IBD 的风险较低（aHR 0.76，95%CI 0.60-0.95；-趋势=0.004）和溃疡性结肠炎（aHR 0.69，95%CI 0.53-0.91；-趋势=0.001），但不是克罗恩病（aHR 0.95，95%CI 0.62-1.45；-趋势=0.765）。小鼠模型表明，槲皮素预处理可以减轻化学诱导的结肠炎。槲皮素摄入量较高与 IBD 风险降低相关，尤其是 UC。槲皮素的保护作用在人类中很有前景，值得进一步研究其下游机制。
